RxDoctor Payments Data

Toni Steele

Family · Greensburg, PANPI 1225557812

Payments from drug & device makers

$3,150in general payments, 2019–2025

Across 186 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$904
  • Neurocrine Biosciences, Inc.$237
  • Alkermes, Inc.$164
  • Lundbeck LLC$147
  • Supernus Pharmaceuticals, Inc.$96
  • plus $453 from 7 others

What the payments were for

  • Food & beverage$2,97294%
  • Education$1786%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,150 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,092
Medicare patients
23
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl74$104,634
TrintellixVortioxetine Hydrobromide52$29,213
LybalviOlanzapine/Samidorphan Malate17$28,785
Lisdexamfetamine Dimesylate22$6,701
Bupropion XlBupropion Hcl100$6,280
Aripiprazole146$4,967
Perphenazine76$4,355
Venlafaxine Hcl ErVenlafaxine Hcl182$3,762
Chlorpromazine Hcl27$3,757
Asenapine Maleate14$3,505
Carbamazepine ErCarbamazepine20$3,420
Risperidone150$3,154
Lamotrigine213$2,738
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine45$2,589
Buspirone Hcl150$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,148$104,63474 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$80$29,21352 claims
Alkermes, Inc.Lybalvi$164$28,78517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →